Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: A Multi‐Institutional Analysis

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective analysis predicts overall survival in metastatic castration-resistant prostate cancer, indicating potential clinical utility.

Developed a nomogram predicts a 1-year survival probability after cabazitaxel treatment.
Study analyzed 345 patients with metastatic castration-resistant prostate cancer, achieving C-indices of 0.72 and 0.67 for validation.
Utilized a Cox proportional hazard model to assess multiple risk factors for overall survival.
Validated nomogram aids in clinical decision-making by distinguishing risk groups based on survival outcomes.

Suzuki et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis predicts overall survival in metastatic castration-resistant prostate cancer, indicating potential clinical utility.